Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.29 USD
Change Today -0.24 / -1.45%
Volume 203.9K
LMNX On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/14 - $21.69
52 Week Low
02/3/15 - $15.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUMINEX CORP (LMNX)

Related News

No related news articles were found.

luminex corp (LMNX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMNX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics and life sciences industries worldwide. It offers xMAP technology, an open architecture, multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The company’s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; respiratory viral family of products, including respiratory viral panel to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel family of products, such as in vitro diagnostic (IVD) assays to identify the pathogens causing infectious gastroenteritis. In addition, the company offers MultiCode assays and products comprising HSV1/2 kits, analyte specific reagents, and other products to detect infectious agents in clinical samples; cystic fibrosis family of products comprising IVD kits for cystic fibrosis genotyping; personalized medicine family of products consisting of assays to determine the drug metabolism status; and specialty product family and instrumentation products, as well as operates an original equipment manufacturer of custom reagents and instrumentation. It serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

745 Employees
Last Reported Date: 02/25/15
Founded in 1995

luminex corp (LMNX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $275.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $370.8K
Chief Marketing & Sales Officer and Senior Vi...
Total Annual Compensation: $334.3K
Total Annual Compensation: $332.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $327.0K
Compensation as of Fiscal Year 2014.

luminex corp (LMNX) Key Developments

Luminex Corporation Announces Launch of the NxTAG Respiratory Pathogen Panel

Luminex Corporation announced the launch of the NxTAG Respiratory Pathogen Panel (RUO). The NxTAG Respiratory Pathogen Panel is the only respiratory assay that enables laboratories to both simultaneously detect 22 respiratory pathogens in a single closed tube system and accommodate the higher throughput required to respond to seasonal changes in demand. The NxTAG Respiratory Pathogen Panel requires only minutes of hands-on time and no upstream reagent preparation. Extracted samples are added directly to pre-plated, lyophilized reagents. The tubes are then sealed and ready for closed tube amplification and subsequent detection using the Luminex MAGPIX instrument. The innovative tube strip design offers laboratories the flexibility to manage variable sample demand by processing a single sample or up to 96 samples per run without wasting consumables or reagents. The NxTAG Respiratory Pathogen Panel total turnaround time is approximately three hours for 96 samples (excluding extraction). The accompanying SYNCT™ Software provides a comprehensive approach to data analysis and reporting, and integrates the NxTAG Respiratory Pathogen Panel easily into any laboratory. Clinical trials for the NxTAG Respiratory Pathogen Panel are in progress in the U.S.

Luminex Corporation Endorses Mix&GoTM Activation Kit of Anteo Technologies Pty Ltd

Anteo Technologies Pty Ltd. announced that to provide shareholders with the link to a blog posted by Luminex Corporation that describes the performance and benefits of using Anteo Mix&GoTM (AMG) Activation Kit for Multiplex Microspheres on the Luminex xMAP platform. In line with Anteo Technologies' product pipeline development strategy, the company launched the AMG Activation Kit for Multiplex Microspheres in December 2014 to assist users of Luminex systems to more easily transfer their existing ELISA assays onto the Luminex platform. The AMG Activation Kit also allows users to troubleshoot proteins that are difficult to attach to Luminex microspheres using other methods. As previously reported, a number of Luminex partners are now engaged with Anteo and one is engaged in a study with clinical samples that is scheduled to conclude this quarter.

Luminex Corporation Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay

Luminex Corporation announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay. Luminex plans to seek both FDA clearance and CE IVD marking in 2015. The clinical trials are being conducted at several clinical laboratories in the U.S. and Luminex expects its FDA submission for ARIES and the HSV 1&2 Assay to occur in the summer of 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $16.29 USD -0.24

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $52.31 USD -0.44
HealthStream Inc $26.05 USD -0.03
Merge Healthcare Inc $5.48 USD -0.11
Meridian Bioscience Inc $18.59 USD -0.33
Quidel Corp $23.70 USD -0.90
View Industry Companies

Industry Analysis


Industry Average

Valuation LMNX Industry Range
Price/Earnings 17.8x
Price/Sales 3.0x
Price/Book 2.2x
Price/Cash Flow 16.6x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at